160 related articles for article (PubMed ID: 31895449)
1. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Bach RG; Cannon CP; Blazing MA
JAMA Cardiol; 2020 Feb; 5(2):235-236. PubMed ID: 31895449
[No Abstract] [Full Text] [Related]
2. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Weingärtner O; Sijbrands EJG; Lütjohann D
JAMA Cardiol; 2020 Feb; 5(2):234. PubMed ID: 31895451
[No Abstract] [Full Text] [Related]
3. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Li D; McCaw ZR; Wei LJ
JAMA Cardiol; 2020 Feb; 5(2):235. PubMed ID: 31895431
[No Abstract] [Full Text] [Related]
4. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Sharma A; Sun JL; Lokhnygina Y; Roe MT; Ahmad T; Desai NR; Blazing MA
Am J Cardiol; 2019 Apr; 123(8):1193-1201. PubMed ID: 30739657
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
[TBL] [Abstract][Full Text] [Related]
6. [Letter].
Poli A
G Ital Cardiol (Rome); 2015 Dec; 16(12):739-40. PubMed ID: 26667952
[No Abstract] [Full Text] [Related]
7. [The IMPROVE-IT trial].
Menozzi A; Lina D; Urbinati S; Greco C
G Ital Cardiol (Rome); 2015 Dec; 16(12):667-71. PubMed ID: 26667942
[No Abstract] [Full Text] [Related]
8. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM
Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828
[TBL] [Abstract][Full Text] [Related]
9. Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project.
Maddox TM; Tang F; Downs JR; Masoudi FA; Virani SS; Daugherty SL; Rumsfeld JS
JAMA Intern Med; 2017 Jun; 177(6):887-889. PubMed ID: 28437531
[TBL] [Abstract][Full Text] [Related]
10. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White J; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2016 Mar; 133(13):e463. PubMed ID: 27022050
[No Abstract] [Full Text] [Related]
11. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
12. [The IMPROVE-IT trial showed no favorable effects on well-defined and clinically relevant endpoints].
Mascitelli L; Goldstein MR
G Ital Cardiol (Rome); 2015 Dec; 16(12):739. PubMed ID: 26667950
[No Abstract] [Full Text] [Related]
13. Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Frishman WH
Am J Med; 2015 Nov; 128(11):1160-1. PubMed ID: 26184685
[No Abstract] [Full Text] [Related]
14. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
15. Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
Hernandez-Mijares A; Bañuls C; Rovira-Llopis S; Diaz-Morales N; Escribano-Lopez I; de Pablo C; Alvarez A; Veses S; Rocha M; Victor VM
Atherosclerosis; 2016 Apr; 247():40-7. PubMed ID: 26868507
[TBL] [Abstract][Full Text] [Related]
16. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6(1):131-139.
Ahmed MH; Saad RA; Osman MM
Expert Opin Drug Saf; 2006 Jul; 5(4):487-8. PubMed ID: 16774486
[No Abstract] [Full Text] [Related]
18. Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Packard C; Stezhka T
Expert Rev Cardiovasc Ther; 2015 May; 13(5):465-6. PubMed ID: 25865021
[TBL] [Abstract][Full Text] [Related]
19. Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
Michos ED; Martin SS; Blumenthal RS
Circulation; 2015 Sep; 132(13):1218-20. PubMed ID: 26330413
[No Abstract] [Full Text] [Related]
20. Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Robinson JG
Circulation; 2016 Mar; 133(13):e461. PubMed ID: 27022048
[No Abstract] [Full Text] [Related]
[Next] [New Search]
